News and Events
Sharing Stories of
Patients, Employees
and Communities
Featured News
June 06, 2023
Alkermes Announces Final Award in Janssen Pharmaceutica Arbitration and Provides Updated Financial Expectations
June 01, 2023
Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc
Our Commitment to Responsibility
Corporate responsibility has always played a central role in our business and has proven even more critical during the past year as we faced some of the most pressing public health and societal issues of our time – a dynamic global pandemic, systemic racism in the U.S. and around the world, and a worsening climate change crisis. Guided by our purpose and values, we took actions to respond to these critical issues, while sharpening our focus on scientific and business excellence in our efforts to help people living with complex and difficult-to-treat diseases. Our most recent Corporate Responsibility Report expounds on these efforts.
Our Stories
Each endeavor at Alkermes starts with collaboration and our shared commitment to make a difference for patients and our communities. These stories – which highlight our people, science and innovation, and leadership perspectives – showcase just a subset of what makes us proud to be part of Alkermes. Visit our full gallery of stories by clicking on the link below.
Cultivating a Healthy Workplace
Hear from Steve Schiavo on Alkermes' commitment to being a recovery-friendly workplace.
HBA Rising Star 2023
We’re proud to recognize Swetha Krishnan, Senior Director of Quality, as our 2023 Healthcare Businesswomen’s Association (HBA) Rising Star – a testament to her leadership and commitment to excellence.
Showcasing Alkermes’ Commitment to the Sleep Community
Hear from Markus Haeberlein, Ph.D. where he discusses our commitment to researching potential treatment options for people living with sleep disorders.
Media Resources
Company Description
Alkermes is focused on developing innovative medicines that seek to address unmet needs of people living with serious mental illness, addiction and cancer. As a fully-integrated, global biopharmaceutical company, with U.S. locations in Massachusetts and Ohio, and locations in Dublin and Athlone, Ireland, we apply our scientific expertise and proprietary technologies to develop products designed to make a meaningful difference in the way people manage their diseases. Beyond our scientific pursuits, we also work to help support and enhance the systems through which these complex diseases are treated. We are committed to patient engagement, disease education and supporting policies that enable access to approved treatment options.
Follow us on our social channels
